Avidity Biosciences is a privately held biotech company pioneering a new class of precision medicines - Antibody-siRNA Conjugates (ASC) - which combine the strengths of monoclonal antibodies and siRNA-based therapeutics. Avidity Biosciences is working with partners to discover best-in-class drug candidates against important undrugged therapeutic targets. Avidity has entered research collaborations with leading biopharma companies and are actively seeking additional partnerships.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/05/17 | $16,000,000 | Series B |
Alethea Capital Management Alexandria Real Estate Equities Brace Pharma EcoR1 Capital F-Prime Capital Partners Moore Venture Partners Takeda Pharmaceutical Company Tavistock Life Sciences | undisclosed |
| 10/17/18 | undisclosed |
CureDuchenne Ventures | undisclosed | |
| 11/13/19 | $100,000,000 | Series C |
Alethea Capital Management Alexandria Venture Investments Boxer Capital Brace Pharma Cormorant Asset Management CureDuchenne Ventures EcoR1 Capital Logos Capital Partner Fund Management Perceptive Advisors RTW Investments  ST Pharm | undisclosed |
